

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



DECLARATION OF FRANK
GRAHAM, PhD.
Examining Group 1636
Patent Application
Docket No. AdVec10CA
Serial No. 09/909,414

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: : Frank L. Graham, et al.
Examiner : Vogel, Nancy T.
Art Unit : 1636
Docket No. : AdVec10CA
Serial No. : 09/909,414
Filed : 07/19/2001
For: : Recombinase-based System for Construction of Adenovirus

Commissioner of Patents
P.O. Box 1450
Alexandria, VA, 22313-1450

Dear Sir or Madam:

DECLARATION OF FRANK L. GRAHAM, PhD. UNDER 37 CFR 1.132

I Frank L. Graham, Ph.D. hereby declare and say as follows:

THAT, I was formerly employed, for a period of 27 years, as Professor in the Department of Biology and the Department of Pathology, McMaster University, Hamilton, Ontario;

THAT, I earned my Ph.D. in the Department of Medical Biophysics, at the University of Toronto, Toronto, Ontario, Canada in 1970;

THAT, I am one of the above-named Applicants and inventors of the subject matter described and claimed in the above-identified patent application;

THAT, I have studied the application Serial No. 09/909,414 and all office actions which have been issued during prosecution of this application, as well as all responses which have been filed on the Applicants behalf, and being thus duly qualified declare as follows:

Prior to the filing date of the parent (application serial number 09/263,650) of the present

continuation application, Serial No. 09/909,414, I had conceived of using the FLP/rtt recombinase enzyme/target site as well as Cre/loxP, for the purpose of achieving site-specific recombination between two different nucleic acid sequences being recombined to generate infectious adenoviral DNA. Application Serial No. 09/909,414 (as well as its parent) discloses such invention. For instance, the specification of application Serial No. 09/909,414 references the use of FLP on page 15, line 13, page 16, line 28, page 26, line 13, page 27, line 17, and page 29, line 10. I further note that on page 27, line 17, an article by O'Gorman et al. (Science, 251:1351 (1991)) is incorporated by reference. This article illustrates the state of the art as to FLP and the rtt target site. In my opinion, this information, by supplementing the teachings of the invention in the specification, assists one skilled in the art to practice the invention using FLP with rtt target sites. A copy of the O'Gorman et al. article is provided as an attachment to this declaration.

Further, subsequent to having demonstrated that Cre/loxP functions to practice the invention disclosed in application Serial No. 09/909,414, with embodiments of such demonstration being provided in the specification of that application, I, with other researchers, conducted experiments to compare the use of FLP/rtt with the use of Cre/loxP in the invention of application Serial No. 09/909,414. The following scientific article, published after the filing date of parent application Serial No. 09/263,650, presents data from those experiments:

Yeast recombinase FLP functions effectively in human cells for construction of adenovirus vectors.

Ng P, Cummings DT, Eveleigh CM, Graham FL.

Biotechniques. 2000 Sep;29(3):524-6, 528. (PMID: 10997266)


A copy of this article is provided as an attachment to this declaration.

Thus, having first conceived of use of Cre and similar site-specific recombinases for site-specific recombination to generate recombinant adenoviral vector constructs, as disclosed in the parent application and in the present continuation application, and having then

demonstrated that this invention works by conducting experiments with the Cre/loxP recombinase/target site combination, and having included in the specification the conception and disclosure that like recombinases, in particular FLP (and its target site, frt) are substitutable in place of Cre/loxP for such purpose, it is my opinion that one skilled in the relevant art, where the level of skill is high, would have been able to practice the invention using FLP/frt without undue experimentation. This is corroborated by the results of the above-noted Ng et al. research article, which demonstrated that, consistent with an expectation based on their similarities, FLP/frt works as well as Cre/loxP in the invention.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements in the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the U.S.C. and that such willful false statements made jeopardize the validity of the application or of any patent issuing thereon.

Further declarant sayeth naught.


Frank Graham, Ph.D.

Nov. 11, 2003
Date

Yeast Recombinase FLP Functions Effectively in Human Cells for Construction of Adenovirus Vectors

BioTechniques 29:524-528 (September 2000)

ABSTRACT

We have recently developed a high-efficiency method of constructing adenovirus vectors based on Cre-mediated recombination between two plasmids co-transfected into 293 cells. The simplicity and efficiency of this method should greatly expedite the construction of most recombinant vectors. However, this system would not be suitable for constructing vectors bearing loxP sites elsewhere in the genome because of undesirable Cre-mediated vector rearrangements. To address this, we have developed a similar system using FLP-mediated site-specific recombination for the construction of adenovirus vectors.

INTRODUCTION

Adenoviruses (Ads) are excellent mammalian gene transfer vectors because of their stability, their ability to efficiently infect a wide variety of quiescent and proliferating cell types from various species to direct high-level viral gene expression, the relative ease with which their 36-kb dsDNA genome can be manipulated by molecular biology techniques and the ease by which they can be propagated and purified to high titers. Consequently, Ads are extensively used as vectors for recombinant vaccines, high-level protein production in cultured cells and gene therapy (2,8,10,12).

A popular method for constructing Ad vectors relies on homologous recombination between two plasmids co-transfected into 293 cells (3). In this method, foreign DNA is inserted into a small shuttle plasmid that contains the left end of the Ad genome including the inverted terminal repeat (ITR), the packaging signal and a multiple cloning region in place of E1 for foreign DNA insertion. The second plasmid contains the entire Ad genome modified to be

noninfectious. Foreign DNA is rescued into recombinant viruses by *in vivo* homologous recombination between overlapping Ad sequences following co-transfection of 293 cells. This method offers several advantages over others for its simplicity, but the efficiency of vector rescue is low because of inefficient homologous recombination.

We recently improved the efficiency of the two-plasmid rescue method 100-fold over the original approach by inserting a *loxP* site into the plasmids and substituting Cre-mediated for homologous recombination and by replacing the single ITR in the shuttle plasmids with an ITR junction (13,14). The simplicity, efficiency and reliability of this method make it ideal for the routine construction of most Ad vectors. However, this method is incompatible with the construction of vectors that have *loxP* sites elsewhere in the genome designed, for example, to regulate transgene expression (1,4,7) or to inhibit vector packaging ability (15).

We addressed this limitation by developing a two-plasmid rescue method based on FLP-mediated site-specific recombination and compared it with the *Crc/loxP* system. FLP-mediated recombination can now be used as an alternative to Cre-mediated recombination when the latter is unsuitable or undesirable for vector construction.

MATERIALS AND METHODS

The plasmids used in these studies were constructed by standard protocols, prepared by the alkaline lysis method (5) and purified by CsCl-density gradient centrifugation. The FLP expression cassette in pBHGFrtAE1,3FLP was a generous gift from Volker Sandig, Merck Research Laboratories (West Point, PA, USA). Propagation of 293 cells (9) and co-transfections were performed as described (11). β -galactosidase expression from viral or mock-infected cells was determined by X-Gal staining as described (13).

RESULTS AND DISCUSSION

We recently described a simple and efficient method of constructing Ad

vectors based on Cre-mediated site-specific recombination between two plasmids co-transfected into 293 cells (13,14). Since the use of Cre recombinase may not always be desirable, we developed an alternative method based on site-specific recombination between *frt* sites catalyzed by FLP recombinase (6) and compared the two systems by rescuing vectors expressing β -galactosidase (Figure 1).

The shuttle plasmids used in this study, pCA35loxAITR and pCA35frtAITR, are shown in Figure 2. Essential features include an ITR junction, a packaging signal and a LacZ expression cassette, followed by a *loxP* site in pCA35loxAITR or an *frt* site in pCA35frtAITR. The Ad genomic plasmids used in this study, pBHGlloxAE1,3Cre and pBHGFrtAE1,3FLP, have a deletion of the E1 region including the packaging signal, rendering them noninfectious (Figure 2). A *loxP* or an *frt* site has been inserted near the 5' end of the pIX gene of pBHGlloxAE1,3Cre and pBHGFrtAE1,3FLP, respectively, to permit site-specific recombination with the appropriate shuttle plasmid. The Cre or FLP expression cassette has been inserted in pBHGlloxAE1,3Cre and pBHGFrtAE1,3FLP, respectively, to provide transient recombinase expression and induce site-specific recombination following co-transfection of any Ad5 E1-complementing cell line. The recombinase expression cassettes were inserted into the Ad genomic plasmid so that they are not rescued into the recombinant vector following site-specific recombination (Figure 1) (14).

To compare the efficiencies of Cre- versus FLP-mediated vector 293 cells were co-transfected with the appropriate combination of plasmids, and the numbers of plaques generated were counted (Table 1). As seen from our previous study (13,14), high-efficiency vector rescue was achieved by Cre-mediated recombination following co-transfection of 293 cells with pCA35loxAITR and pBHGlloxAE1,3Cre as evident by the large numbers of plaques generated (Table 1). Similar numbers of plaques were obtained following co-transfections with pCA35frtAITR and pBHGFrtAE1,3FLP, indicating that the efficiencies of Cre- and FLP-mediated vector rescue were comparable. We

Short Technical Reports

Table 1. Vector Rescue Efficiency by Cre- versus FLP-Mediated Recombination^a

Shuttle plasmid	Ad genomic plasmid	Plaques/dish (Average/dish)	
		Experiment 1	Experiment 2
pCA35loxΔITR	pBHGloxΔE1,3Cre	59, 45, 45 (50)	52, 57, 31, 42 (45.5)
pCA35frtΔITR	pBHGfrtΔE1,3FLP	45, 41, 44, 45 (44)	39, 40, 31, 44 (38.5)

^a60-mm dishes of 293 cells were co-transfected with 2 μg each plasmid, and plaques were counted 10 days after co-transfection.

previously showed that all analyzed plaques that were generated by Cre-mediated recombination had the correct DNA structure and expressed the foreign transgene (13,14). To determine if this was also the case for FLP-mediated vector rescue, 21 plaques were isolated for analysis. All plaques had the expected DNA structure as determined by restriction enzyme analysis of the vector DNA, and all were positive for β-galac-

tosidase expression (data not shown).

Construction of Ad vectors by these approaches offers several advantages over other methods. (i) The method requires only two steps—insertion of the foreign DNA into a small (3–4 kb) shuttle plasmid, followed by co-transfection of 293 cells with an Ad genomic plasmid. (ii) Only plasmid DNA are required as substrates that can be propagated in any routinely used *E. coli*

strain. (iii) Unlike other methods that require linearization of plasmid DNA before transfection, neither the shuttle plasmid nor the genomic plasmid requires restriction endonuclease digestion. This is especially important if the restriction enzyme site used to release the Ad genome is also present in the foreign DNA, thus rendering these methods unsuitable. (iv) Many plaques, which start to appear as early as five days after co-transfection, are obtained to virtually guarantee successful vector rescue. (v) All plaques have the expected DNA structure and express the foreign transgene.

We have now constructed a variety of shuttle plasmids to permit cloning of virtually any foreign DNA up to about 8 kb for Ad vector construction by either Cre- or FLP-mediated recombination. These shuttle plasmids and the Ad genomic plasmids used in these studies can be obtained from Microbix Biosystems (www.microbix.com). We and




Figure 1. Construction of Ad vectors by Cre- or FLP-mediated site-specific recombination following co-transfection of 293 cells with Ad genomic plasmid (pBHGloxΔE1,3Cre or pBHGfrtΔE1,3FLP) and shuttle plasmid (pCA35loxΔITR or pCA35frtΔITR). Ad and bacterial plasmid sequences are represented by thick and thin lines, respectively, and loxP or frt sites are represented by arrowhead. LoxP and frt are the target sites for Cre and FLP recombinase, respectively.




Figure 2. Plasmids used to rescue Ad vectors expressing β -galactosidase. The shuttle plasmids pCA35lox Δ ITR and pCA35frr Δ ITR contain an ITR junction, a packaging signal (ψ), a LacZ expression cassette and a loxP site in the former and an frr site in the latter. The noninfectious Ad genomic plasmid pBHGlox Δ E1,3Cre (14) contains the entire Ad5 genome except for deletions of E1 including ψ and E3, a loxP site 5' of the pIX gene and a Cre expression cassette in place of E1. The plasmid pBHGfrr Δ E1,3FLP is identical to pBHGlox Δ E1,3Cre except for replacement of the loxP with an frr site and the Cre with the FLP expression cassette. Thick and thin lines represent Ad and bacterial plasmid sequences, respectively. Arrowhead represents loxP or frr sites, and small black arrows represent ITRs.

others at McMaster University have now rescued a wide variety of expression cassettes into Ad vectors by these methods with efficiencies comparable to those reported here for the LacZ cassette. The possibility of choosing between two different recombinases, both functioning with high efficiency, allows maximum flexibility in the design of recombinant Ad vectors.

REFERENCES

- Anton, M. and F.L. Graham. 1995. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. *J. Virol.* 69:4600-4606.
- Berkner, K.L. 1988. Development of adenovirus vectors for expression of heterologous genes. *BioTechniques* 6:616-629.
- Bett, A.J., W. Haddara, L. Prevec and F.L. Graham. 1994. An efficient and flexible sys-

tem for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. *Proc. Natl. Acad. Sci. USA* 91:8802-8806.

- Bilbao, G., H. Zhang, J.L. Contreras, T. Zhou, M. Feng, I. Saito, J.D. Mountz and D.T. Curiel. 1999. Construction of a recombinant adenovirus vector encoding Fas ligand with a Cre/loxP inducible system. *Transplant. Proc.* 31:792-793.
- Birnboim, H.C. and J. Doly. 1978. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res.* 7:1513-1523.
- Broach, J.R., V.R. Guarascio and M. Jayaram. 1982. Recombination with the yeast 2 μ plasmid is site specific. *Cell* 29:227-234.
- Fujino, M., X.-K. Li, T. Okuyama, N. Funeshima, A. Tamura, S. Enosawa, Y. Kita, T. Amano et al. 1999. On/off switching Fas ligand gene expression in liver by Cre/loxP adenovirus vector system. *Transplant. Proc.* 31:753-754.
- Graham, F.L. and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines. p. 363-389. In R.W. Ellis (Ed.), *Vaccines: New Approaches to Immunological*

- Problems. Butterworth-Heinemann, Boston.
- Graham, F.L., J. Smiley, W.C. Russell and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus 5. *J. Gen. Virol.* 36:59-72.
- Hitt, M., C.L. Addison and F.L. Graham. 1997. Human adenovirus vectors for gene transfer into mammalian cells. *Adv. Pharmacol.* 40:137-206.
- Hitt, M., A. Bett, L. Prevec and F.L. Graham. 1998. Construction and propagation of human adenovirus vectors, p. 500-512. In J.E. Celis (Ed.), *Cell Biology: A Laboratory Handbook*, 2nd ed. Academic Press, San Diego.
- Hitt, M.M., R.J. Parks and F.L. Graham. 1999. Structure and genetic organization of adenovirus vectors, p. 61-86. In T. Friedman (Ed.), *The Development of Human Gene Therapy*. CSH Laboratory Press, Cold Spring Harbor, NY.
- Ng, P., R.J. Parks, D.T. Cummings, C.M. Eveleigh, U. Sankar and F.L. Graham. 1999. A high efficiency Cre/loxP based system for construction of adenoviral vectors. *Hum. Gene Ther.* 10:2667-2672.
- Ng, P., R.J. Parks, D.T. Cummings, C.M. Eveleigh and F.L. Graham. 2000. An enhanced system for construction of adenoviral vectors by the two plasmid rescue method. *Hum. Gene Ther.* 11:693-699.
- Parks, R.J., L. Chen, M. Ashton, U. Sankar, M.A. Rudnicki and F.L. Graham. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc. Natl. Acad. Sci. USA* 93:13565-13570.

This work was supported by grants from the National Institutes of Health, the Medical Research Council (MRC), the National Cancer Institute of Canada (NCIC) and by Merck Research Laboratories. P.N. is supported by an MRC Postdoctoral Fellowship. Address correspondence to Dr. Frank L. Graham, Department of Biology and Pathology, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1 Canada. e-mail: graham@mcmaster.ca

Received 9 March 2000; accepted 15 May 2000.

Philip Ng, Derek T. Cummings, Carole M. Eveleigh and Frank L. Graham
*McMaster University,
 Hamilton, ON, Canada*

tain two zooxanthella RFLPs: the group C RFLP plus a unique RFLP generated by one nucleotide substitution that creates a Taq I site in the larger of the two RFLP C fragments (14). These two RFLPs either represent two distinct algae or a polymorphism within the multicopy ssRNA genes of one alga. Some other digests contain extra fragments that may identify additional ssRNA sequences. These represent small PCR amplification products that cannot be complete ssRNA genes (for example, Fig. 1C, lanes 1 and 6), or they are not interpretable from the available data; where those products occur, they occur in all individuals of that host species.

16. Replicates (Table 1) were collected from different locations so that distinct individuals, as opposed to members of one or a few clones, were sampled.

17. C. Yanisch-Perron, J. Viciara, J. Messing, *Gene* 33, 103 (1985).

18. In phylogenetic analyses, sequences determined from cloned PCR-amplified ssRNA genes include an uncertainty owing to the possibility of DNA replication errors during PCR, and of sequence polymorphism within multicopy ssRNA genes [M. L. Sogin,

in *PCR Protocols: A Guide to Methods and Applications*, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, Eds. (Academic Press, New York, 1990), pp. 307-314]. Replicate sequencing suggests that this uncertainty is on the order of one or two nucleotides for the ssRNA region that we studied (13).

19. M. J. Kevin, W. T. Hall, J. J. A. McLaughlin, P. A. Zahl, *J. Phycol.* 5, 341 (1969).

20. M. L. Sogin, A. Ingold, M. Karlok, H. Nielsen, J. Engberg, *EMBO J.* 5, 3625 (1986).

21. T. W. Vaughan and J. W. Wells, *Spec. Papers Geol. Soc. Am.* 44 (1943).

22. The validity of using RFLP genotypes to classify these zooxanthellae is explicitly demonstrated by their concordance with the phylogenetic groups defined by ssRNA sequences (Fig. 3).

23. A. G. Coates and J. B. C. Jackson, *Paleobiology* 13, 363 (1987); G. D. Stanley, Jr., *Geology* 9, 507 (1981).

24. I. Leizerovich, N. Kardish, M. Galun, *Symbiosis* 8, 75 (1990).

25. T. F. Goreau, *Science* 145, 383 (1964); P. W. Glynn, *Environ. Conserv.* 10, 149 (1983).

26. J. Maynard Smith, *The Evolution of Sex* (Cambridge Univ. Press, Cambridge, MA, 1978).

27. L. W. Buss, *The Evolution of Individuality* (Princeton Univ. Press, Princeton, NJ 1987).

28. T. H. Jukes and C. R. Cantor, in *Mammalian Protein Metabolism*, H. N. Munro, Ed. (Academic Press, New York, 1969), pp. 21-132.

29. J. Felsenstein, *PHYLIP Version 3.2 Manual* (University of California Herbarium, Berkeley, CA, 1989).

30. R.R. thanks L. Brezinsky, C. Kanechika, and T. Humphrys for hospitality and laboratory space on Oahu, and colleagues at the West Indies Laboratory and the National Undersea Research Center on St. Croix for their help in collecting specimens. M. A. Coffroth supplied *Plexaura* A samples. L. Park and C. Patton got the PHYLIP programs running. Supported by an NSF Postdoctoral Fellowship in Marine Biotechnology (R.R.) and by a contract from the National Undersea Research Center, National Oceanic and Atmospheric Administration.

17 August 1990; accepted 19 December 1990

Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells

STEPHEN O'GORMAN,* DANIEL T. FOX, GEOFFREY M. WAHL

A binary system for gene activation and site-specific integration, based on the conditional recombination of transfected sequences mediated by the FLP recombinase from yeast, was implemented in mammalian cells. In several cell lines, FLP rapidly and precisely recombined copies of its specific target sequence to activate an otherwise silent β -galactosidase reporter gene. Clones of marked cells were generated by excisional recombination within a chromosomally integrated copy of the silent reporter. By the reverse reaction, integration of transfected DNA was targeted to a specific chromosomal site. The results suggest that FLP could be used to mosaicly activate or inactivate transgenes for analysis of vertebrate development, and to efficiently integrate transfected DNA at predetermined chromosomal locations.

RECENT ANALYSES OF MAMMALIAN development have made use of transfected genes to alter cell interactions and trace cell lineages. This inherently powerful approach could be applied to investigate a broader range of developmental processes if it was possible to restrict transgene expression to specific subsets of the cells, tissues, or developmental stages in which the cis-acting sequences that typically control expression are active. Such mosaic expression is essential for many forms of lineage analyses and would additionally provide a means to assess the effects of transgenes that grossly alter development in small patches of tissue within an otherwise normal embryo. Toward this end, we have characterized a conditional recombination system based on the site-specific recombinase, termed FLP (1), from *Saccharomyces cerevisiae*. In this system, gene activation requires prior FLP-mediated excisional recombina-

tion, and expression therefore falls under the binary control of the transgene's own cis-acting sequences and those that direct FLP expression. Reversal of this excisional recombination, under different experimental conditions, provides a means for introducing DNA into specific sites in mammalian chromosomes.

Table 1. β -Galactosidase activities in cotransfection assays of 293, CV-1, and F9 cells. Positive control transfections (pFRT β GAL) included 1 μ g of pFRT β GAL and 18 μ g of the pOG28 (6) non-FLP control plasmid. Negative control transfections (pNEO β GAL) included 1 μ g of pNEO β GAL and 18 μ g of pOG28. Experimental transfections (pNEO β GAL + FLP) contained 1 μ g of pNEO β GAL and 18 μ g of the pOG44 FLP expression plasmid (Fig. 1A). The pNEO β GAL + FLP values are also shown as a percentage of the pFRT β GAL positive control values. Each value represents the mean and SEM of six plates from two experiments. Neither pOG28 nor pOG44 generated β -galactosidase activity when transfected alone (5). Transfections and assays were performed as described in the legend to Fig. 1. All transfections contained 1 μ g of pRSVL to correct β -galactosidase activities for relative transfection efficiencies.

Cell line	β -Galactosidase activity (units/mg protein)			
	pFRT β GAL	pNEO β GAL	pNEO β GAL + FLP	pNEO β GAL + FLP / pFRT β GAL (%)
293	30.4 \pm 1.9	0.17 \pm 0.02	14.2 \pm 2.2	47
CV-1	275 \pm 25	0.33 \pm 0.06	22.6 \pm 1.2	8
F9	24.8 \pm 4.3	0.04 \pm 0.01	1.88 \pm 0.02	8

Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037.

*To whom correspondence should be addressed.

A cotransfection assay was used to characterize FLP-mediated recombination of extrachromosomal DNA in a variety of cell lines. Cells were transfected with an expression construct and a "reporter" plasmid that was a substrate for the recombinase. The activity of the expression construct was assayed either by recovering the transfected reporter and looking for molecular evidence of recombination or by preparing cytoplasmic extracts to measure β -galactosidase activity generated by precisely recombined reporter molecules.

The pNEO β GAL reporter plasmid used in these assays was derived from pFRT β GAL (Fig. 1A). pFRT β GAL contains the bacterial β -galactosidase coding sequence, which has been modified by insertion of an FLP recombination target site (FRT) immediately 3' to the translational start (2). The FRT consisted of the two inverted 13-base pair (bp) repeats and 8-bp spacer that comprise the minimal FLP target (3, 4) plus an additional 13-bp repeat that may augment reactivity of the minimal sub-

strate (4). The insertion preserved the β -galactosidase translational reading frame and pFRT β GAL generated robust activity in mammalian cells (Table 1). pNEO β GAL was constructed by cutting pFRT β GAL within the FRT with Xba I and then inserting an Xba I fragment that consisted of two half-FRT sites flanking a neomycin transcription unit (2). This created intact FRTs on each side of the neomycin cassette and rendered the β -galactosidase transcription unit inactive (Table 1). Because the two FRT sites in pNEO β GAL are tandemly arrayed, precise FLP-mediated recombination of the FRTs would be expected to excise the neomycin cassette, re-create the parental pFRT β GAL plasmid, and restore β -galactosidase expression.

Cotransfection of cells with a fixed amount of pNEO β GAL and increasing amounts of an FLP expression vector (pOG44) generated increasing amounts of recombined reporter plasmid and β -galactosidase activity. Molecular evidence for FLP-mediated recombination was obtained by recovering plasmids 36 hours after transfection, followed by restriction endonuclease treatment and Southern (DNA) blotting (Fig. 1B). Lysates of cells from cotransfections that included pOG44 showed a signal at 5.6 kb, which corresponds to the size of recombined reporter (equivalent to pFRT β GAL), and a 3.2-kb signal that was generated by unrecombined pNEO β GAL

receptor (Fig. 1A). The 5.6-kb band intensity was proportional to the amount of FLP expression plasmid included in the transfection, and this band was not seen in cotransfections in which a non-FLP plasmid was substituted for the FLP expression vector (Fig. 1B) or in transfections that only contained pOG44 (5). The pOG44 vector generated additional signals at 2.2 and 2.8 kb because it contained sequences homologous to the probe (6). In the same samples, β -galactosidase activity was also proportional to the amount of FLP expression plasmid included (Fig. 1C). Only background activities were observed in cotransfections that included a non-FLP control plasmid (Table




Fig. 2. Histochemical demonstration of β -galactosidase activity in cell lines with a single integrated copy of pNEO β GAL after transfection with the pOG44 FLP expression plasmid. (A) CVNEO β GAL/E26 cells 48 hours after transfection. Cells that express β -galactosidase contain a blue reaction product. (B) Border between positive and negative colonies of CVNEO β GAL/E25 cells 2 weeks after transfection. (C) The B2 subclone of CVNEO β GAL/E25 after 8 weeks of culture. (D) A mixed colony of CVNEO β GAL/E25 cells 1 week after transfection showing both positive and negative cells. CVNEO β GAL/E cells growing under G418 selection were transferred to nonselective medium and transfected 24 hours later with pOG44 as described in the legend to Fig. 1. Cells were histochemically processed (26) either with (A and D) or without (B and C) prior resuspension.

1) or when pOG44 alone was transfected (5). The experiment thus provides both molecular and biochemical evidence for precise FLP-mediated recombination.

This paradigm was used to demonstrate FLP activity in monkey kidney (CV-1) and mouse embryonal carcinoma (F9) cells. In Table 1, the β -galactosidase activities in the "pFRT β GAL" transfections represent an estimate of the expression expected if all the pNEO β GAL in a cotransfection immediately underwent recombination. The highest relative expression in pNEO β GAL plus pOG44 cotransfections, 47%, occurred in 293 cells; this is a high level of activity considering that β -galactosidase expression required prior FLP expression and recombination of pNEO β GAL. Cotransfections of CV-1 and F9 cells generated 8% of the activity seen in the pFRT β GAL transfections. Even this lower relative activity clearly marked cotransfected cells in histochemical reactions for β -galactosidase activity (5).

For this method of gene activation to be useful in transgenic mice, FLP would need to routinely mediate recombination of FRTs integrated at a single site in the mammalian genome. Cell lines that contained single integrated copies of pNEO β GAL (designated CVNEO β GAL/E) were isolated by transfecting CV-1 cells with linearized plasmids by electroporation, selecting G418-resistant (G418^R) transfectants that stably expressed the neomycin cassette, and identifying single copy lines by Southern blot analyses (5) (Fig. 3). As previously shown for other integrated constructs with similarly short direct repeats (7), the chromosomal FRTs did not spontaneously recombine to produce a β -galactosidase-positive (β GAL⁺) phenotype at detectable frequencies (Table 2).

Transient expression of FLP in the CVNEO β GAL/E lines promoted a rapid conversion to a β GAL⁺ phenotype. When five different cell lines were transfected with pOG44, β -galactosidase activities after 36

Fig. 1. Cotransfection assay for FLP-mediated recombination of extrachromosomal DNA. (A) pFRT β GAL, pNEO β GAL, and the pOG44 FLP expression vector (6). Half-arrows, positions of FRT sites; E and S, Eco RI and Sca I restriction sites, respectively; Psv, early promoter from SV40; BETA-GAL, β -galactosidase coding sequence; NEO, neomycin expression cassette; Pcmv, cytomegalovirus immediate-early promoter; IN, intron; FLP, FLP coding sequence; AN, SV40 adenylation cassette. Thin lines represent vector sequences; thick lines in the pOG44 diagram represent sequences homologous to the probe. Sizes of restriction fragments are indicated in kilobase pairs (kb). (B)

Southern blot of Hirt lysates (21) prepared from 293 (human embryonic kidney) (22) cells transfected with 1 μ g of pNEO β GAL and varying amounts of pOG44. A non-FLP control plasmid (pOG28) (6) was included as needed to keep the total amount of plasmid and Pcmv constant. Sizes of fragments (kilobase pairs) are shown at right. Lysates were digested with Eco RI and Sca I, and Southern blots were probed with a β -galactosidase probe (Fig. 1A). The identities of the hybridizing bands were confirmed with additional digests and probes. (C) β -Galactosidase activities in the same transfections shown in (B). Subconfluent cultures of cells growing in Dulbecco's minimum essential medium and 5% calf serum in 10-cm dishes were transfected by overnight exposure to calcium phosphate precipitates (23) and then divided into four lots. After 24 hours of incubation, one plate of each transfection was harvested by Hirt extraction (21), and a second plate was used to prepare cytoplasmic extracts (24). Approximately 5% of the DNA recovered from single plates was used for Southern analyses. β -Galactosidase assays were performed as described (25). Luciferase activities generated by the inclusion of 1 μ g of pRSVL (24) in all transfections were used to correct β -galactosidase activities for relative transfection efficiencies. The experiment was repeated twice with similar results.




Table 2. β -Galactosidase phenotypes of CVNEO β GAL/E cell lines (which contain a single inactive copy of the pNEO β GAL reporter) after transfection with FLP expression (pOG44), non-FLP negative control (pOG28), or β -galactosidase positive control (pFRT β GAL) plasmids. The pFRT β GAL transfections included 1 μ g of pFRT β GAL and 19 μ g of pOG44; other mixes contained 20 μ g of the indicated plasmid. β -Galactosidase activities are mean values for triplicate transfections performed as described in the legend to Fig. 1 and assayed 36 hours after removal of precipitates; SEM values for the pOG44 transfections were less than 10% of the means. The β -galactosidase phenotype of cells was determined by scoring more than 10^3 cells after transfection and histochemical processing as described in the legend to Fig. 2.

Cell line	β -Galactosidase activity (units/mg protein)		β GAL ⁺ cells (%)		
	pOG28	pOG44	pOG28	pFRT β GAL	pOG44
E6	0.24	11.2	0*	8.7	6.1
E25	0.21	16.7	0*	17.1	12.4
E26	0.18	7.2	0*	19.5	15.4
E14	0.28	13.1	ND	ND	ND
E22	0.09	9.6	ND	ND	ND

*No positive cells were detected among $>10^6$ cells examined. ND, not determined.

hours were 40 to 100 times as high as those seen in replicate plates transfected with a non-FLP plasmid (Table 2). At 48 hours after transfection, histochemical processing showed many β GAL⁺ cells (Table 2 and Fig. 2A). To provide some estimate of the efficiency of recombination, we prepared an additional set of replicate plates that were transfected with pFRT β GAL. A comparison of the fractions of β GAL⁺ cells in the pFRT β GAL and in the pOG44 transfections suggests, assuming similar transfection efficiencies, that most of the cells (70 to 80%) transfected with pOG44 were converted to a β GAL⁺ phenotype (Table 2). The comparison undoubtedly underestimates the efficiency of FLP-mediated excision because many copies of a functional β -galactosidase gene were available for immediate transcription in the positive controls, whereas recombination may have oc-

curred only shortly before harvest in some pOG44-transfected cells; in these cases, the single recombined reporter gene may not have generated enough β -galactosidase by the time of harvest to render the cells positive in the assay.


The β GAL⁺ phenotype was passed on to all descendants of many FLP-converted cells. Positive colonies were formed when transfected cells were plated at low densities (Fig. 2B), and β -galactosidase expression persisted during prolonged expansion of individual colonies (Fig. 2C). Entirely negative colonies (Fig. 2B) and mixed colonies (Fig. 2D) were also observed. Mixed colonies would be expected if recombination occurred after mitosis in only one descendant of a transfected cell, or if recombined and unrecombined cells mixed at replating or during subsequent growth. Indeed, the physical segregation of phenotypes evident

in most mixed colonies suggested that they were composed of stably positive and negative lineages (Fig. 2D).

The correlation between β -galactosidase expression and recombination at FRT sites was examined by comparing the structure of the integrated pNEO β GAL sequences in two β GAL⁺ subclones to the parental line. CVNEO β GAL/E25 (E25) cells (10^6) were transfected with pOG44 and subcloned 12 hours after removal of the precipitate. After histochemical screening, two β GAL⁺ subclones (E25B1 and E25B2) were expanded for further analysis. In Southern blots of genomic DNA from both subclones, the pattern of hybridization matched that expected for FLP-mediated recombination of the FRT sites in the parental line (Fig. 3). In Eco RI digests, the 3.2-kb fragment of E25 was lost and 2.0 kb of DNA were added to an 8.5-kb junctional fragment to create a 10.5-kb junctional fragment in the derived lines. The other (3.7-kb) junctional fragment and the internal 2.0-kb fragment were unchanged. Although recombination products have not been recovered and sequenced, these Southern analyses and the fact that activation of β -galactosidase expression required creation of functional translational reading frame suggest that the preponderance of FLP-mediated recombination was precise.

Reversal of this excisional recombination could in principle be used to target the integration of transfected plasmids containing an FRT to specific genomic sites. To compare the frequency of such site-specific integration to the frequency of integration at random sites, we cotransfected G418-sensitive, β GAL⁺ E25B2 cells with pOG44 and a plasmid, pOG45, that contained a neomycin resistance gene expression cassette and a single FRT (8). We expected that G418^R colonies formed after site-specific integration of pOG45 would be β -galactosidase-negative (β GAL⁻), whereas those formed by random integration would be β GAL⁺. G418^R subclones (designated B2N) were histochemically stained and more than half were found to be either entirely β GAL⁻, or predominantly β GAL⁻ with a few clusters of β GAL⁺ cells (Table 3). The remaining colonies were β GAL⁺. With continued passage as dispersed monolayers, the fraction of β GAL⁺ cells in the mixed lines rapidly diminished. The possibility that they were G418-sensitive cells that initially survived because of their proximity to resistant cells was confirmed by reconstitution experiments (5). All of the colonies formed after parallel cotransfections of pOG44 and control plasmids containing the same neomycin cassette but lacking an FRT were β GAL⁺ (Table 3).

Fig. 3. Analysis of genomic DNA from a cell line with a single integrated copy of pNEO β GAL (CVNEO β GAL/E25 or E25), two derivative β GAL⁺ subclones (E25B1, E25B2), and two subclones derived from E25B2 after cotransfection with pOG45 and pOG44 (B2N1, B2N2). (A) Top, pattern of plasmid integration in E25 deduced from Southern blot analysis; middle, predicted pattern for β GAL⁻ subclones of E25 if precise recombination across the FRTs occurred; bottom, predicted pattern for β GAL⁺ G418^R subclones of E25B2 after FLP-mediated insertion of pOG45. Abbreviations and symbols as in Fig. 1A; except here P denotes the SV40 early promoter; β -GAL, β -galactosidase coding sequence; thin lines represent genomic DNA; and pOG45 sequences are indicated by cross-hatching. The sizes of hybridizing fragments are given in kilobase pairs. (B) Southern blot of Eco RI-digested genomic DNA from the E25 parental line, the E25B1 and E25B2 subclones, and the B2N1 and B2N2 subclones of E25B2. The sizes of hybridizing fragments (kilobase pairs) are indicated at the left. The pattern predicted for precise FLP-mediated recombination was observed in all derived subclones (Fig. 3A). The probe was random-primed pNEO β GAL (Fig. 1A). The identities of the bands were confirmed with additional digests and probes.



The fidelity with which loss of β -galactosidase activity was caused by the expected recombination of chromosomal and plasmid FRTs, resulting in the integration of a single unarranged copy of pOG45 within the β -galactosidase sequence of the E25B2 line, was examined by Southern analyses. Because the FRT and neomycin cassette of pOG45 were derived from the neomycin cassette and 3' FRT of pNEO β GAL (Fig. 1A) (8), recombination of the plasmid FRT with the E25B2 chromosomal FRT would be expected to regenerate the 3.2-kb Eco RI fragment of the original E25 parent. Additionally, the 8.5-kb junctional fragment of E25 would be expected to shift to 12.0 kb because pOG45 is 3.5 kb larger than the neomycin cassette of pNEO β GAL. Finally, the 3.7-kb junctional fragment and the 2.0-kb internal fragment of the E25 and E25B lines would be expected to be unchanged in the B2N lines. These predictions were met in each of the eight β GAL⁻ or mosaic B2N lines analyzed, as shown for two lines in Fig. 3B. In contrast, each of the four β GAL⁺ colonies examined by Southern analyses had integrated pOG45 at a random genomic site (5).

Our data show that FLP-mediated recombination can target the integration of transfected DNA to a specific chromosomal site at frequencies that exceed those of random integration, and that the event can be marked by an alteration in gene activity at the target site. The efficiency of targeted integration could potentially be increased by using ratios of the integrating and FLP expression vectors different from those used here, or by using FRT mutations in the plasmid and chromosomal sites to decrease the frequency at which successfully integrated plasmids are subsequently excised (9). The β -galactosidase-marking paradigm could be combined with a promoter-trap strategy, similar to that used to demonstrate site-specific integration mediated by the Cre recombinase (10). This would greatly increase the relative frequency of site-specific events.

Previous descriptions of recombinase-mediated rearrangement of chromosomal sequences in *Drosophila* (11) and mammalian cells (12) have not directly addressed the question of whether site-specific recombinases could routinely create a functional translational reading frame, as we have now shown. Moreover, the efficiency of this FLP-based system appears to be much higher than that reported in the only other description of site-specific recombination of chromosomal sequences in mammalian cells (12). Transient expression of the Cre recombinase in mouse L cells was shown to effect a 25-fold increase in the incidence of a selectable phenotype that required rear-

Tabl 3. Numbers of G418^R colonies with β GAL⁺ and β GAL⁻ phenotypes formed after transfection of E25B2 cells with plasmids that contained a neomycin resistance gene and that additionally either did (+FRT) or did not (-FRT) contain an FRT. All transfections also included an FLP expression vector. Colonies were scored as β GAL⁻ if they were completely or predominantly β GAL⁻, β GAL⁺ colonies were always entirely positive. In one experiment (Exp 1), 10⁶ cells were transfected by electroporation in 0.8 ml of phosphate-buffered saline containing 39 μ g of pOG44 and 1 μ g of either pOG45 (+FRT) or pMC1neo (27) (-FRT). In a second experiment (Exp 2), 10⁶ cells were transfected by overnight exposure to calcium phosphate precipitates containing 19 μ g of pOG44 and 1 μ g of either pOG45 (+FRT) or pOG45A (8) (-FRT) as described in the legend to Fig. 1. Colonies were scored by histochemical assay (26) after 14 to 18 days of growth in the presence of G418.

	Number of G418 ^R colonies			
	+FRT		-FRT	
	β GAL ⁺	β GAL ⁻	β GAL ⁺	β GAL ⁻
Exp 1	30	46	23	0
Exp 2	24	58	32	0

rangement of chromosomally integrated Cre targets. The much greater signal-to-noise ratio seen in our FLP system (>10⁶) is in part due to the low rate at which integrated copies of pFRT β GAL spontaneously recombine, and may additionally reflect differences inherent to the recombinases or differences in the vectors used for their expression. Construction of pOG44 was guided by reports that transcript splicing can enhance or diminish expression. An intron was inserted within the untranslated leader to increase expression (13) and care was taken to eliminate cryptic splice acceptor sites (14) that are found immediately 3' to the native FLP structural sequence (15). The latter could inactivate transcripts by inappropriately splicing to cryptic donor sites in the FLP structural sequence (16).

Earlier FLP constructs containing the structural sequence and 3' flanking sequences in pSV2 (17) or pCDM8 (18) vectors were inactive in some cell lines and considerably less active than pOG44 in others (5). Surprisingly, their activity, but not that of pOG44, increased two to five times after heat shock at 45°C (5). As a possible explanation for this augmented expression, we propose that the accumulation of unspliced transcripts in mammalian cells after heat shock (19) would transiently decrease inappropriate splicing and increase the number of functional FLP transcripts, an effect that may have contributed to the robust heat shock-induced expression of FLP seen in *Drosophila* (11, 20).

FLP-mediated recombination of marker genes has the potential to provide the basis for new forms of lineage analysis in a variety of organisms. An initial step in this direction was described in a recent report: heat shock-induced expression of FLP was used to excise, and thereby inactivate expression of, a transfected pigmentation marker in order to delineate retinal clones in *Drosophila* (11). The utility of such loss-of-function marking paradigms, however, is limited to tissues and organisms for which both a positive genetic marker and a negative genetic background are available. The approach additionally requires that the marker gene be present in a single copy so that individual recombination events reverse cellular phenotype. These conditions are only exceptionally met in *Drosophila* and would be more rarely met in mice. In contrast, the gain of function β -galactosidase marking system described here could be used for lineage analyses in a wide variety of tissues in different organisms. The reporter was normally silent, spontaneously activated at very low frequencies, and was efficiently activated by FLP. The gain of function was heritable and easily detected with a simple histochemical assay. In transgenic mice, the lineages marked by recombination would be determined by the promoters used to drive FLP expression. These could include promoters that were only transiently active at a developmental state that substantially preceded overt differentiation. Because transcription of the β -galactosidase construct would be controlled by an independent set of cis-acting sequences, recombined reporter genes could be expressed at later developmental stages, after differentiation had occurred. By this means it would be possible to construct a fate map for mammalian development that correlated embryonic patterns of gene expression with the organization of mature tissues.

REFERENCES AND NOTES

1. J. R. Broach and J. B. Hicks, *Cell* 21, 501 (1980).
2. The oligonucleotide used for the construction of pFRT β GAL was 5'-GATCCCGGGCTACCATGGAAGTTCCTATTTCGAAGTTCCTATTTCCTAGAAAGTATAGGAAGTTC-3'. This contained an in-frame start codon (bold), minimal FRT site (underlined), and an additional copy of the 13-bp FRT repeat (between center dots); the Xba I site within the FRT spacer is enclosed in parentheses. The linker was inserted between the Bam HI and Hind III sites of pSKS105 [M. J. Casadaban, A. Martin-Arias, S. K. Shapira, J. Chou, *Methods Enzymol.* 100, 293 (1983)] and the lacZ portion of the modified gene was cloned into a pSV2 vector (17). The neomycin cassette used for construction of pNEO β GAL was an Xho I-Bam HI fragment from pMC1neo-polyA (27) cloned between copies of the J3 FRT site (4) in pUC19.
3. R. M. Gronostajski and P. D. Sadowski, *J. Biol. Chem.* 260, 12320 (1985); J. F. Senecoff, R. C. Bruckner, M. M. Cox, *Proc. Natl. Acad. Sci. U.S.A.* 82, 7270 (1985).
4. M. Jayaram, *Proc. Natl. Acad. Sci. U.S.A.* 82, 5875 (1985).

5. S. O'Gorman and G. M. Wahl, unpublished observations.
6. pOG44 consisted of the cytomegalovirus immediate-early promoter from pCDM8 (18), a 5' leader sequence and synthetic intron from pMLSIscat (13), the FLP coding sequence [nucleotides 5568 to 6318 and 1 to 626 of the 2- μ m circle (15)], and the SV40 late region polyadenylation signal from pMLSIscat (13). The following silent nucleotide substitutions were introduced into the structural FLP sequences with the use of the polymerase chain reaction: C for T at position 5791 (15), G for A at 5794, G for C at 5800, C for T at 55, G for A at 58, and C for T at 55, G for A at 58, and C for T at 103. These changes eliminated three canonical AATAAA polyadenylation signals and introduced a Pst I restriction site without altering the amino acids encoded by the sequence. These alterations did not appear to significantly affect the expression of FLP by mammalian cells. pOG28 consisted of a murine cDNA for dihydrofolate reductase (6) cloned into pCDM8.
7. R. J. Bollag, A. S. Waldman, R. M. Liskay, *Annu. Rev. Genet.* 23, 199 (1989).
8. pOG45 consisted of the neomycin resistance cassette and 3' FRT from pNEO β GAL cloned into pUC19. pOG45A was derived from pOG45 by deleting a 200-bp fragment containing the FRT.
9. J. F. Senecoff, P. J. Rossmeissl, M. M. Cox, *J. Mol. Biol.* 201, 405 (1988).
10. B. Sauer and N. Henderson, *New Biologist* 2, 441 (1990).
11. K. G. Golic and S. Lindquist, *Cell* 59, 499 (1989).
12. B. Sauer and N. Henderson, *Nucleic Acids Res.* 17, 147 (1989).
13. M. T. F. Huang and C. M. Gorman, *ibid.* 18, 937 (1990).
14. S. M. Mount, *ibid.* 10, 459 (1982).
15. J. L. Hardy and J. E. Donelson, *Nature* 286, 860 (1980).
16. M. T. F. Huang and C. M. Gorman, *Mol. Cell. Biol.* 10, 1805 (1990).
17. P. J. Southern and P. Berg, *J. Mol. Appl. Genet.* 1, 327 (1982).
18. A. Aruffo and B. Seed, *Proc. Natl. Acad. Sci. U.S.A.* 84, 8573 (1987).
19. U. Bond, *EMBO J.* 7, 3509 (1988).
20. H. J. Yost and S. Lindquist, *Cell* 45, 185 (1986).
21. B. Hirt, *J. Mol. Biol.* 26, 365 (1967).
22. F. L. Graham, J. Smiley, W. C. Russell, R. Naim, *J. Gen. Virol.* 36, 59 (1977).
23. F. L. Graham and A. J. van der Eb, *Virology* 52, 456 (1973).
24. J. de Wet, K. V. Wood, M. DeLuca, D. R. Helinski, S. Subramani, *Mol. Cell. Biol.* 7, 725 (1987).
25. C. V. Hall, P. E. Jacob, G. M. Ringold, F. Lee, *J. Mol. Appl. Genet.* 2, 101 (1983).
26. J. R. Sanes, J. L. R. Rubenstein, J.-F. Nicolas, *EMBO J.* 5, 3133 (1986).
27. K. Thomas and M. Capecchi, *Cell* 51, 503 (1987).
28. We thank M. McKeown, R. Heyman, and R. Evans for their insightful contributions to this work and the preparation of the manuscript. M. Jayaram provided the FRT and FLP coding sequences. Supported by Xerox Corporation, Bayer A. G., the Weingart Foundation, and the Mathers Foundation.

28 August 1990; accepted 8 January 1991

Multiple Representations of Pain in Human Cerebral Cortex

JEANNE D. TALBOT, SEAN MARRETT, ALAN C. EVANS, ERNST MEYER, M. CATHERINE BUSHNELL, GARY H. DUNCAN*

The representation of pain in the cerebral cortex is less well understood than that of any other sensory system. However, with the use of magnetic resonance imaging and positron emission tomography in humans, it has now been demonstrated that painful heat causes significant activation of the contralateral anterior cingulate, secondary somatosensory, and primary somatosensory cortices. This contrasts with the predominant activation of primary somatosensory cortex caused by vibrotactile stimuli in similar experiments. Furthermore, the unilateral cingulate activation indicates that this forebrain area, thought to regulate emotions, contains an unexpectedly specific representation of pain.

DESPITE THE POWERFUL NATURE OF pain as a sensation, there is little consensus regarding the involvement of the cerebral cortex in pain processing. Early this century, Head and Holmes (1) observed individuals with war injuries and concluded that the cerebral cortex played only a minimal role in pain perception. Penfield and Boldrey (2) reached a similar conclusion when they found that patients rarely reported a sensation of pain

on electrical stimulation of their exposed cerebral cortex during surgery to remove epileptic seizure foci. Thus, a commonly held view in clinical neurology is that "stimulation of . . . any . . . cortical areas in a normal, alert human being does not produce pain" (3).

Other data indicate that several areas of the cerebral cortex may process nociceptive information. Some patients with epileptic foci involving the primary or secondary somatosensory areas of the parietal lobe (SI and SII, respectively) experience pain during seizures (4). In addition, lesions of these areas in humans can sometimes lead to reduced pain perception (5). Single neurons in both SI and SII of the parietal cortex of awake monkey respond to nociceptive stimuli (6); however, these findings are so rare

that the functional significance of parietal nociceptors is still in question.

Frontal cortex has also been implicated in pain processing. In cat and in humans, noxious electrical stimuli induce an increase in cerebral blood flow to the frontal lobes (7). In rat there are neurons in the prefrontal cortex that respond to noxious skin stimulation (8). In addition, in patients resection of the anterior cingulate cortex can reduce the distress associated with chronic intractable pain (9). Nevertheless, the unreliable nature of this surgical procedure in relieving pain (10) and the absence of precise anatomical data from humans, uncompromised by disease or lesions, underscore our lack of knowledge concerning the normal function of specific cortical regions in pain processing.

We have now investigated the involvement of specific cortical areas in the perception of pain in awake, healthy, human volunteers. To functionally isolate the perception of pain from all other sensory and behavioral variables, we used subtractive positron emission tomography (PET). This technique can identify subtle differences in the activation of specific brain sites relative to sensory and evaluative processes (11, 12). In addition, we have applied methods (13, 14) that combine into stereotaxic images the functional information derived




Fig. 1. (A) The perceived intensity of the thermal stimuli. Intensity ratings (mean \pm SD) given by the eight subjects immediately after the PET scans in which the thermal stimuli were 41° to 42°C (Warm) or 47° to 49°C (Heat Pain). The ratings were different between the two conditions (paired *t* test, *t* = 12.7, *P* < 0.0001). (B) Mean pulse rate (\pm SD) of the eight subjects during 2-min epochs before, during, and after the termination of the PET scans during the Warm (○) and Heat Pain (●) conditions. A repeated-measures multivariate analysis of variance revealed no significant changes in pulse rate over time [*F*(2) = 0.05, *P* = 0.95] nor between the Warm and Heat Pain conditions [*F*(1) = 0.73, *P* = 0.38].

J. D. Talbot, M. C. Bushnell, G. H. Duncan, Laboratoire de neurophysiologie comportementale, Faculté de médecine dentaire, Université de Montréal, Montréal, Québec, Canada H3C 3J7.

S. Marrett, A. C. Evans, E. Meyer, Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Québec, Canada H3A 2B4.

*To whom correspondence should be addressed.